CoChat
Sign Up
Cited by 229Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.

Atorvastatin Causes Insulin Resistance and Increases Ambient Glycemia in Hypercholesterolemic Patients

Open access
Koh, Kwang Kon, Quon, Michael J., Han, Seung Hwan, Lee, Yonghee, Kim, Soo Jin, Shin, Eak Kyun·2010·Journal of the American College of Cardiology
DOI 10.1016/j.jacc.2009.10.053PMC PMC3016087
Open this paper in CoChat — free account

Abstract

Objectives We investigated whether atorvastatin might decrease insulin sensitivity and increase ambient glycemia in hypercholesterolemic patients.Background Clinical trials suggest that some statin treatments might increase the incidence of diabetes despite reductions in low-density lipoprotein (LDL) cholesterol and improvement in endothelial dysfunction.Methods A randomized, single-blind, placebo-controlled parallel study was conducted in 44 patients taking placebo and in 42, 44, 43, and 40 patients given daily atorvastatin 10, 20, 40, and 80 mg, respectively, during a 2-month treatment period.Results Atorvastatin 10, 20, 40, and 80 mg significantly reduced LDL cholesterol (39%, 47%, 52%, and 56%, respectively) and apolipoprotein B levels (33%, 37%, 42%, and 46%, respectively) after 2 months of therapy when compared with either baseline (all p < 0.001 by paired t test) or placebo (p < 0.001 by analysis of variance [ANOVA]). Atorvastatin 10, 20, 40, and 80 mg significantly increased fasting plasma insulin (mean changes: 25%, 42%, 31%, and 45%, respectively) and glycated hemoglobin levels (2%, 5%, 5%, and 5%, respectively) when compared with either baseline (all p < 0.05 by paired t test) or placebo (p = 0.009 for insulin and p = 0.008 for glycated hemoglobin by ANOVA). Atorvastatin 10, 20, 40, and 80 mg decreased insulin sensitivity (1%, 3%, 3%, and 4%, respectively) when compared with either baseline (p = 0.312, p = 0.008, p < 0.001, and p = 0.008, respectively, by paired t test) or placebo (p = 0.033 by ANOVA).Conclusions Despite beneficial reductions in LDL cholesterol and apolipoprotein B, atorvastatin treatment resulted in significant increases in fasting insulin and glycated hemoglobin levels consistent with insulin resistance and increased ambient glycemia in hypercholesterolemic patients. (Effects of Atorvastatin on Adiponectin Levels and Insulin Sensitivity In Hypercholesterolemic Patients; NCT00745836).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2009.10.053

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 27 references

1 of the 27 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Items 201–229 of 229

Related

See all

Metadata

Authors
Koh, K. K., Quon, M. J., Han, S. H., Lee, Y., Kim, S. J., & Shin, E. K.
Affiliations
  • Gachon University Gil Medical Center (KR)
  • National Institutes of Health (US)
  • University of Seoul (KR)
Corresponding author
Koh, Kwang Kon
ORCID
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2010-03
Volume
55
Issue
12
Pages
1209-1216
ISSN
0735-1097 (ISSN-L)
DOI
10.1016/j.jacc.2009.10.053
PMC
PMC3016087
OpenAlex
W2052703897
Cited by
229
References
27
Citations by year
2026: 4 · 2025: 10 · 2024: 9 · 2023: 16 · 2022: 9 · 2021: 8 · 2020: 5 · 2019: 13 · 2018: 9 · 2017: 11 · 2016: 13 · 2015: 18 · 2014: 31 · 2013: 23 · 2012: 23
FWCI
24.66
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • established investigator award
  • Gachon University Gil Hospital
  • Intramural Research Program, National Center for Complementary and Alternative Medicine, National Institutes of Health
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
atorvastatin, insulin resistance, hypercholesterolemia, statins, fasting insulin, HbA1c, LDL cholesterol, apolipoprotein B, diabetes risk, dose-dependent effects, endothelial dysfunction, endothelial nitric oxide synthase, nitric oxide, nitric oxide synthase inhibition, hypertriglyceridemia
MeSH terms
Atorvastatin, Adult, Aged, Blood Glucose, Double-Blind Method, Female, Heptanoic Acids, Humans, Hypercholesterolemia, Insulin, Insulin Resistance, Male, Middle Aged, Pyrroles, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review